MEET YOUR NEW NEIGHBORSNeighborhood is a community of entrepreneurs, innovators, regulatory experts, health tech consultants and industry KOLs working together to accompany health tech startups to their next significant valuation milestones.
Would like to learn more
on our programs or take a tour?
Cardiology, neurology, stroke
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
Technion – Israel Institute of Technology
The Technion – Israel Institute of Technology is a public research university in Haifa, Israel. Established in 1968, the Faculty of Biomedical Engineering has a multidiciplinary scope nurturing research activities that blend medical and biological engineering. Research projects have resulted in the development of patented medical aids. Recent research breakthroughs include the identification of a structured neurological code for syllables and could let paraplegics "speak" virtually through the connection of the brain to a computer.
Cystic Fibrosis, Polycystic kidney disease, neurodegenerative diseases.
ManRos Therapeutics develops novel drug candidates acting against severe pathologies, namely cystic fibrosis, neurodegenerative disorders (Alzheimer’s disease and Down syndrome), and some renal diseases (including polycystic kidney disease). Anomalies in phosphorylation are observed in the three pathologies on which ManRos Therapeutics carries out its research: they share common targets and similar mechanisms.
OP2 Innovative Drugs
OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in the preclinical stage, with a strong scientific rationale. Based on strategic partnerships in Europe and in the US, we are generating growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinical in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.
LE HUB BPI FRANCE – HEALTHTECH
Pour accompagner les startups de la santé (biotech, medtech et e-santé), Bpifrance lance un nouvel accélérateur et dévoile la première promotion. Le Hub HealthTech vise à mieux connecter les entreprises du secteur à leur écosystème pour favoriser leur croissance et leur développement.
L’accélérateur HealthTech du Hub se focalise sur l’accompagnement des participations biotech, medtech et e-santé en post-amorçage de Bpifrance en leur proposant un programme sur-mesure, adapté aux problématiques propres au secteur (temps de développement, problématiques réglementaires, besoins capitalistiques, etc.).